Skip to content

Author

Ruo-Yu Xing

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial.

Evaluated the immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) compared with MF59-adjuvanted egg-derived quadrivalent influenza vaccine (aQIV) and recombinant quadrivalent influenza vaccine (QIVr) in adults aged 50 years or older.

Brandon J. Essink, Wim Vermeulen, Coralie Andrade et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.